悦康药业：子公司YKYY032注射液获得NMPA和FDA临床试验批准

Core Viewpoint - Yuyuan Pharmaceutical (688658.SH) announced that its subsidiary, Beijing Yuyuan Ketech Pharmaceutical Technology Co., Ltd., and Hangzhou Tianlong Pharmaceutical Co., Ltd. have received NMPA approval for clinical trials of YKYY032 injection for the treatment of hyperlipoproteinemia(a) [1] Group 1 - The YKYY032 injection is a chemically synthesized double-stranded siRNA drug that utilizes RNA interference to specifically silence the mRNA of the LPA gene, thereby blocking the production of lipoprotein(a) [Lp(a)] from the source [1] - The approval from both NMPA and FDA for the clinical trial application of YKYY032 marks a significant milestone in the company's new drug development [1] - The drug development process is lengthy, involves multiple stages, and carries high risks, indicating that it will not have a significant impact on the company's short-term performance [1]